Brain shrinkage in MS: new study aims to compare treatment effectiveness

NCT ID NCT05962177

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 400 people with relapsing-remitting multiple sclerosis to see how their brains change over three years. Researchers will use MRI scans and blood tests to compare those on high-efficacy treatments versus medium-efficacy ones. The goal is to understand which treatments better slow brain atrophy, a key sign of disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors choose better treatments to slow brain shrinkage in multiple sclerosis patients.

What could go wrong

This is an observational study, not a treatment trial. It will not directly test a new drug or cure, and results may not change care immediately.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Neurology Department, Hopital Gui de Chauliac

    RECRUITING

    Montpellier, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••